Transforming Allergy Treatment

R & D

Allergy Vaccines

Allergy Vacines

AT's current portfolio of competitive products includes products containing allergoids, (modified allergens) tyrosine depot and MPL® adjuvant. These technologies offer significant benefits over older allergy vaccination technologies. AT's development programme is designed to improve product characteristics e.g. provide an improved safety profile and reduce the number of injections over the treatment period, resulting in well-accepted registered products likely to be prescribed by a higher percentage of physicians.

Read more

Research & Development

Research and development

Allergy Therapeutics has a long-term commitment to research and in particular development of innovative therapies for both the treatment and prevention of allergy-related conditions. Included in this section are details of our current clinical programme and a selection of our scientific publications.

Of course due to the nature of R&D projects, this information including the status of these products is subject to change at any time.

Our current list of products in development reflects both in-house efforts and collaborations with outside companies and organisations.

 

Latest Publications

Latest Publication

Cross-reactivity in Grasses: Biochemical Attributes Define Exemplar Relevance.
Bullimore A, Batten T, Hewings S, Fischer von Weikersthal-Drachenberg KJ, Skinner M.
Source.World Allergy Organ J. 2012 Oct;5(10):111-9.
Read the abstract

A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy.
Reeve L, Baldrick P, Hewings S, Skinner M. J Appl. Toxicol. 2012; 32: 608-616

Read the abstract

View all publications